Amyotrophic lateral sclerosis (ALS) is a highly heterogeneous disease with no effective
treatment. Drug development has been hampered by the lack of biomarkers that aid in early
diagnosis, demonstrate target engagement, monitor disease progression, and can serve as
surrogate endpoints to assess the efficacy of treatments. Fluid-based biomarkers may
potentially address these issues. An ideal biomarker should exhibit high specificity and
sensitivity for distinguishing ALS from control (appropriate disease mimics and other …